Assyro AI

FDA Orange Book · active-ingredient family

Baxdrostat

Baxdrostat is approved in 1 FDA application, with therapeutic-equivalence codes, listed patents, and marketing exclusivity from the FDA Orange Book.

Reference-listed drug:BAXFENDY · NDA 219878

1

Brand (NDA)

0

Generics (ANDA)

1

Listed patents

2

Exclusivity periods

Brand (NDA) products · tablet

ProductApplicantApplicationTEApproved
BAXFENDYRLD×2ASTRAZENECA ABNDA 219878May 15, 2026

Marketing exclusivity (2)

  • NCENew chemical entity exclusivity (5 years)

    May 15, 2031

    in 5 yr

  • NCENew chemical entity exclusivity (5 years)

    May 15, 2031

    in 5 yr

Listed patents (1)

Patents listed in the FDA Orange Book for this product, with expiration date and patent type.
PatentExpiresInType
9353081Feb 04, 2033in 6 yr 9 mo
SubstanceProduct

Baxdrostat — frequently asked questions

Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.